Sentinel-node biopsy in melanoma [9]

New England Journal of Medicine

Volumn 356, Issue 4, 2007, Pages 419-

  Kanzler, Matthew H ^a   Levitt, Lee ^a   Lin, Albert ^a  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HUMAN; LETTER; LONG TERM CARE; LYMPHADENECTOMY; MELANOMA; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE BIOPSY; SURVIVAL; LYMPH NODE METASTASIS; METASTASIS; MORTALITY; NOTE; PATHOLOGY; PROGNOSIS; SKIN TUMOR; SURVIVAL RATE;

HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MELANOMA; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 33846419489     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:1431-42.
2. Agnese DM, Abdessalam SF, Burak WE Jr, Magro CM, Pozderac RV, Walker MJ. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003;134:542-7.